Novel blood-based biomarker candidates in screening for colorectal cancer.

Authors

null

Jason Lee Liggett

EDP Biotech Corporation, Knoxville, TN;

Jason Lee Liggett , Mathias M Petersen , Jakob Kleif , Morten Rasmussen , Lars Nannestad Jørgensen , Jakob Benedict Seidelin , Mogens R. Madsen , Jesper Vilandt , Kåre Andersson Gotschalck , Lars M. Andersen , Ali Khalid , Berit Andersen , Ib Jarle Christensen , Herbert A. Fritsche , Eric S. Mayer , Christina Therkildsen

Organizations

EDP Biotech Corporation, Knoxville, TN; , Hvidovre Hospital, Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; , Nordsjællands Hospital, Hillerød, Denmark; , Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; , Bispebjerg University Hospital, Copenhagen, Denmark; , Gastro Unit, Section for Gastroenterology, Herlev Hospital, Herlev, Denmark; , Department of Surgery, Herning Hospital, Herning, Denmark; , Department of Surgery, Nordsjællands Hospital, Hillerød, Denmark; , Department of Surgery, Horsens Hospital, Horsens, Denmark; , Department of Public Health Programmes and University Research Clinic for Cancer Screening, Randers Regional Hospital, Randers, Denmark; , Department of Surgery, Viborg Hospital, Viborg, Denmark; , Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; , Gastro Unit, Hvidovre Hospital, Hvidovre, Denmark; , Fritsche Consulting Services, Houston, TX;

Research Funding

Other
Gastro Unit dept. 360, Hvidovre Hospital, Kettegårds Allé 30, 2650 Hvidovre, Denmark and EDP Biotech Corporation

Background: Colorectal cancer (CRC) is the third most common cancer worldwide motivating national screening strategies utilizing fecal immunochemical tests (FIT). Blood-based biomarkers could be an alternative method to increase compliance in population-based screening programs for early detection of CRC. We aimed to identify new blood-based biomarkers that could be potential candidates for use in colorectal cancer screening. Methods: In a nested cohort study of 1967 FIT positive participants of the Danish CRC screening program serum levels of GDF-15, hepsin, IL-8, keratin1-10, L1CAM, MIA, monocyte MCP-1, NSE and OPG were measured using the Luminex xMAP immunoassay platform. Main outcomes were CRC vs non-CRC and CRC, high-risk adenomas (HRA) or medium-risk adenomas (MRA) vs low-risk adenomas (LRA) or clean colorectum. Odds ratios for associations between biomarker expressions and outcomes were calculated using logistic regression models and visualized by area under the receiver operating characteristic (ROC) curve (AUC). Analyses were made on the Luminex biomarkers alone and with addition of clinical and demographic information. Results: FIT-induced colonoscopies detected 240 CRCs and 625 HRA or MRA. Multivariate analyses using all biomarkers and age found hepsin, IL-8 and OPG significantly (p<0.001) associated in relation to the main outcome (CRC vs non-CRC) with odds ratios of 0.74 [0.59-0.92], 2.59 [2.12-3.15] and 0.90 [0.82-0.99], respectively. The full model using all biomarkers and age presented an AUC of 0.73 [0.70-0.77]. Conclusions: Changed serum levels of nine novel biomarkers seem to be potential predictors for early detection of CRC, especially hepsin, IL-8 and OPG.

Multivariable analysis for the two main study outcomes including all nine biomarkers and age.

CRC versus non-CRCCRC, HRA or MRA versus LRA or clean colorectum
OR95%-CIP valueModel
AUC*
OR95%-CIP valueModel
AUC*
GDF-15
Hepsin
IL-8
Keratin 1-10
L1CAM
MIA
MCP1
NSE
OPG
Age (pr 1 year)
0.76
0.74
2.64
0.90
1.02
0.97
0.91
1.05
0.46
1.07
[0.59-0.98]
[0.59-0.92]
[2.16-3.23]
[0.82-0.99]
[0.82-1.26]
[0.65-1.44]
[0.71-1.16]
[0.83-1.34]
[0.29-0.71]
[1.05-1.09]
0.02
<0.01
<0.01
0.04
0.86
0.87
0.45
0.68
<0.01
<0.01
0.71

0.95
0.94
1.38
0.93
0.94
0.83
1.04
1.03
0.59
1.05
[0.81-1.12]
[0.82-1.08]
[1.21-1.59]
[0.87-0.99]
[0.82-1.08]
[0.64-1.09]
[0.89-1.23]
[0.88-1.20]
[0.45-0.79]
[1.03-1.06]
0.55
0.37
<0.01
0.03
0.38
0.18
0.60
0.70
<0.01
<0.01
0.62

OR: Odds ratio; CRC: colorectal cancer; HRA: high-risk adenoma; MRA: medium-risk adenoma; LRA: low-risk adenoma; CI: confidence interval; AUC: area under the ROC curve. * AUC after 10-fold cross validation repeated 10 times.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 244)

DOI

10.1200/JCO.2023.41.4_suppl.244

Abstract #

244

Poster Bd #

N6

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Annual Meeting

Cost effectiveness of colorectal cancer screening in the Dominican Republic.

First Author: Yoanna S. Pumpalova

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Impact of revising colorectal cancer screening guidelines on health care resources in Canada.

First Author: Brendan Chia

Abstract

2022 ASCO Annual Meeting

Identifying potential glycoproteomic biomarkers for diagnosis of colorectal cancer (CRC).

First Author: Klaus Lindpaintner